New £9m hospital outpatient unit opens
A new hospital facility has opened in Cornwall.
The outpatient department at West Cornwall Hospital in Penzance cost £9m and was completed in early June.
The unit was designed to provide modern, accessible and technically advanced facilities.
Kate Shields, chief executive officer at NHS Cornwall and Isles of Scilly Integrated Care Board, said the department would help deliver treatment "as close to where people live as possible".
More news stories for Cornwall
Listen to the latest news for Cornwall
The new building has technology which enables staff to offer virtual care as well as face-to-face.
Steve Williamson, chief executive officer at the Royal Cornwall Hospitals NHS Trust, said the organisation had "worked tirelessly" with NHS partners and the local community to secure the investment for the unit.
Final year illustration students from Falmouth University were invited to submit works of art for one of their end-of-year modules, all of which are exhibited in the new building.
Work on the build began in February 2024.
Follow BBC Cornwall on X, Facebook and Instagram. Send your story ideas to spotlight@bbc.co.uk.
West Cornwall Hospital build hits milestone
Building work on new Cornish hospital unit starts
Royal Cornwall Hospitals NHS Trust
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Podiatry Practice moves to new location in Salisbury
A podiatry practice has moved to a new location. Sarum Podiatry Practice has relocated from Milford Street to Castle Street, Salisbury. The practice, run by Susan Dawkins, BSc (Hons) MRCOP, HCPC Registered Podiatrist, is now at 56 Castle Street. Ms Dawkins said: "We look forward to seeing you at our new premises." The new location is described as "spacious" and "newly renovated." While the front of the practice is still being refurbished, it is open for business. Contact details remain the same: 01722 500408 or sarumpodiatry@
Yahoo
33 minutes ago
- Yahoo
Medtronic (MDT) Appoints Dr. Joon Sup Lee to Board of Directors
Medtronic plc (NYSE:MDT) is one of the 11 best European stocks to invest in. On June 23, the company announced the appointment of Dr. Joon Sup Lee as an independent director to its Board of Directors. The appointment went into effect on June 18, 2025. A healthcare specialist in the laboratory testing an Oncology-related product. Dr. Lee's appointment was a result of Medtronic increasing the size of its Board. The new director will serve on the Board's Science and Technology Committee and the Compensation and Talent Committee. Dr. Lee is currently the CEO of Emory Healthcare, Inc., overseeing Georgia's most comprehensive academic health system. Before joining Emory Healthcare, Dr. Lee was the executive director of the University of Pittsburgh Medical Center's (UPMC) Heart and Vascular Institute from 2018 to 2020. He was also a professor of medicine at the University of Pittsburgh School of Medicine. He held various leadership roles at UPMC, including Director of Interventional Cardiology and Director of the Cardiac Catheterization Laboratory. Medtronic plc (NYSE:MDT) is an Irish-domiciled healthcare technology company. It develops and sells medical devices and therapies for chronic conditions across four main segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Its top products include heart devices, spinal implants, surgical tools, insulin pumps, and neuromodulation systems. Medtronic serves over 79 million patients annually in more than 150 countries. While we acknowledge the potential of MDT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment
GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA approval for a 200 mg/mL autoinjector of Benlysta (belimumab) for the treatment of active lupus nephritis (LN). The approval applies to children aged five years and above. A pharmacist looking at a prescription bottle of gastrointestinal drugs. Benlysta autoinjector is the first-of-its-kind treatment option for at-home administration. The drug is a B-lymphocyte stimulator (BLyS)-specific inhibiting monoclonal antibody. It works by binding to soluble BLyS, which inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. It does not bind B cells directly. The 200 mg/mL autoinjector was previously approved for pediatric patients with active systemic lupus erythematosus (SLE) in 2024. Benlysta was the first and only approved biologic for both SLE and lupus nephritis in over 50 years, including for the pediatric population. The autoinjector will be available for patients and their caregivers immediately. GSK plc (NYSE:GSK) is a UK-based global biopharmaceutical company. It researches, develops, and sells medicines and vaccines for infectious diseases, HIV, respiratory conditions, cancer, and immune-related disorders. Its key products include Shingrix (shingles vaccine), Nucala (asthma), and HIV treatments through its ViiV Healthcare joint venture. While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
